← Back to Clinical Trials
Recruiting NCT06672588

Magnetic Seizure Therapy for Schizophrenia - Trial

Trial Parameters

Condition Treatment Resistant Schizophrenia
Sponsor Centre for Addiction and Mental Health
Study Type INTERVENTIONAL
Phase N/A
Enrollment 80
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2025-04-22
Completion 2028-11
Interventions
Magnetic Seizure Therapy (MST)Electroconvulsive Therapy (ECT)

Brief Summary

This trial aims to assess the clinical effects and tolerability of Magnetic Seizure Therapy (MST) as an alternative to electroconvulsive therapy (ECT) for Treatment Resistant Schizophrenia (RS).

Eligibility Criteria

Inclusion Criteria: 1. are inpatients or outpatients; 2. demonstrate capacity to consent according to the MacArthur competence assessment tool for clinical research (MacCAT-CR); 3. have a DSM-5 diagnosis of Schizophrenia or Schizoaffective Disorder for at least 2 years, as determined by the MINI International Neuropsychiatric Interview - Version 7 (MINI-7.0); 4. are 18 years of age or older; 5. have demonstrated resistance to at least 2 antipsychotics of 600 mg of chlorpromazine equivalents for at least 6 weeks; 6. have a BPRS score at baseline of at least moderate severity (\>4) on one of the four psychotic items (i.e., hallucinatory behavior, suspiciousness, conceptual disorganization, unusual thought content) or at least 12 on these 4 items combined; 7. are considered to be appropriate to receive convulsive therapy as assessed by an ECT attending psychiatrist and a consultant anaesthesiologist; 8. are on an antipsychotic at an adequate dose and are agreeable to keeping their curr

Related Trials